Shots: The US FDA has accepted the PR for NDA of mirabegron (oral suspension) and sNDA for Myrbetriq (mirabegron, tablets) for neurogenic detrusor overactivity (NDO) in pediatric patients aged ≥ […]readmore
Tags : Oral Suspension
Shots: Novartis recalls three lots of Promacta oral suspension to the consumer level due to the presence of peanut floor contamination occurred at third-party manufacturing facility and is conducted within […]readmore